Drugs / recombinant human G-CSF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01164345 Background | Jun 2010 → May 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma | Sheba Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human G-CSF | “Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.” NCT01164345 ↗ |
| Known as | G-CSF | “G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.” NCT01164345 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human G-CSF” NCT01164345 ↗ |